Noveome Biotherapeutics, Inc.

Noveome Biotherapeutics, Inc. is a US-based biotechnology company focused on developing innovative therapeutics, specifically its proprietary product ST266, which targets critical health conditions across multiple medical fields. Founded in 2000 and headquartered in Pittsburgh, US, Noveome Biotherapeutics, Inc. specializes in the development of advanced biologics.

In April 2025, the company raised USD 51 million in venture funding from unspecified investors. The CEO, Pat Welch, leads the firm as it aims to enhance treatment solutions in healthcare. Noveome Biotherapeutics, Inc. specializes in the development of its core product, ST266, which is a pioneering biologic that operates as a multi-targeted secretome.

This innovative therapeutic includes a vast array of biologically active proteins and factors that play critical roles in neuroprotection, inflammation modulation, and cellular recovery and healing. ST266 is positioned to address significant unmet medical needs, particularly in the fields of ophthalmology, neurology, and dermatology. The company is targeting a diverse range of conditions, including those seen in patients suffering from serious illnesses like necrotizing enterocolitis in premature infants. Geographically, Noveome's products are aimed at markets within the United States, where it seeks to enhance treatment options for both healthcare providers and patients.

Noveome Biotherapeutics generates revenue through strategic partnerships and clinical collaborations, leveraging its proprietary ST266 product in various therapeutic applications. The company enters agreements with healthcare organizations and may engage in B2B transactions where ST266 could be supplied to hospitals or clinics for clinical use. These partnerships involve structured agreements that outline the terms of product supply and utilization within clinical settings. Revenue generation is supported by the clinical efficacy of ST266, as demonstrated in ongoing trials and studies, which enhance the product's value proposition to prospective clients.

Specific pricing details and revenue figures related to ST266 and other offerings are proprietary to the company and not publicly disclosed. Noveome Biotherapeutics plans to advance its pipeline with the continued development of ST266, aiming for new product launches in the near future. The company is also exploring opportunities for expansion into other regions beyond the US, with specific markets yet to be disclosed. The company will use the April 2025 funding to advance clinical trials for its treatment of a rare and often fatal pediatric gastrointestinal disease.